Laccure has launched a product for treatment and prevention of bacterial vaginosis (BV) in the EU that possesses a reported cure rate of 80 per cent after one administration. The product recently received CE mark approval as a Class IIa medical device. Intended to address an unmet need of women suffering from BV infection, the treatment is said to represent a commercial potential in the over-the-counter market.
The non-prescription vaginal tablet has been tested in randomised, controlled, clinical, multicentre studies of 126 women, where it demonstrated a good safety profile and user-friendly delivery. Moreover, the use of this treatment may significantly reduce the need for antibiotics and consequently limit the risk of antibiotic resistance. The product is based on a substance that releases lactic acid over an extended period of time to decrease elevated vaginal pH.